Description
BPC + TB Oral Blend is an oral tablet formulation with BPC-157 and TB-500 in a single dosage form. Instead of two separate subcutaneous injections, the healing stack is administered as oral application.
Per study reports the pharmacology of both compounds remains identical: BPC-157 stimulates growth hormone receptors in tendon fibroblasts and accelerates connective tissue healing; TB-500 modulates actin polymerization for cell migration and angiogenesis.
The central question with oral peptide formulations is bioavailability. In the gastrointestinal tract peptides are enzymatically degraded - oral forms typically reach only 1-5% of subcutaneous bioavailability. Higher oral doses compensate partially, but the action characteristic differs from injection.
In recreational research practice the BPC+TB Oral Blend is used as an adherence-friendly alternative to injection, especially for users who reject regular subcutaneous injections. Direct comparability to subcutaneous application is limited.
Pharmacokinetically: oral bioavailability low, better with fatty meal. Half-life after absorption several hours.
You can order BPC + TB Oral Blend as oral tablets in one bottle with 1mg per tablet.
This information is for research and educational purposes only. No medical recommendations.
Risks & Safety
BPC + TB Oral Blend is considered well tolerated per study reports. Both compounds - BPC-157 and TB-500 - have a mild profile in the preclinical literature, and the oral form additionally avoids injection-related reactions.
Observed in research and user reports:
- Gastrointestinal tract: as an oral form, mild transient gastrointestinal observations (fullness, loose stool) are the most likely.
- Low systemic bioavailability: peptides are enzymatically degraded in the gastrointestinal tract, and the oral form reaches only a fraction of subcutaneous bioavailability - this is primarily an efficacy question, not a safety one.
- Angiogenesis effect of the TB-500 component: because TB-500 is described in the literature as stimulating angiogenesis, a theoretical concern is discussed that existing abnormal tissue could also be supplied. No evidence supports this.
- No long-term data: robust long-term human studies do not exist. The favorable safety profile rests primarily on animal models and short-term anecdotal experience.
This classification does not replace medical advice. Risk and responsibility for any actual use lie entirely with the buyer.
Studies
- Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157, a potential drug for treating various wounds, in rats and dogs - Frontiers in Pharmacology 2022, He et al: BPC-157 PK profile across oral and parenteral routes.
- Stable gastric pentadecapeptide BPC 157 and wound healing - Frontiers in Pharmacology 2021, Seiwerth et al: BPC healing mechanism review.
- The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration - Journal of Applied Physiology 2011, Chang et al: BPC-157 in tendon-fibroblast migration.
- The regenerative peptide thymosin beta-4 accelerates the rate of dermal healing in preclinical animal models and in patients - Annals of the New York Academy of Sciences 2012, Treadwell et al: TB-500 in dermal healing.
- Interaction of thymosin beta-4 with muscle and platelet actin: implications for actin sequestration in resting platelets - Biochemistry 1992, Weber et al: biochemical evidence for actin binding as the core mechanism of TB-500.
